CHRU Strasbourg
CHRU Strasbourg
Strasbourg, France11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessment of Information Provided on Infectious Risk in Solid Organ Transplantation | Pulmonary Transplantation; Transplantation Infection | Not yet recruiting | Not stated | 2026-08-31 | NCT07788417 | |
| A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab | Cryoglobulinemic vasculitis | Recruiting | Phase 2 | 2026-08-31 | NCT07268521 | |
| Effect of the IBAIP in Preterm Infants Neurodevelopment | Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications, Obstetric Labor, Premature, Premature Birth, Urogenital Diseases, pregnancy disorder | Recruiting | Not applicable | 2026-06-26 | NCT04685356 | |
| Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor | graft versus host disease | Recruiting | Phase 3 | 2026-04-27 | NCT06083129 | |
| Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2026-04-08 | NCT03772028 | |
| Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy | brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Not stated | 2025-11-20 | NCT04802135 | |
| Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Recruiting | Not applicable | 2025-09-15 | NCT04029363 | |
| Observatory of Patients With Haemophilia B Treated by IdElvion® | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Not stated | 2025-01-08 | NCT05086575 | |
| Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2024-05-29 | NCT05310591 | |
| Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Recruiting | Phase 2 | 2023-11-24 | NCT05126849 | |
| Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR | Prosthetic Infection | Recruiting | Phase 3 | 2022-05-10 | NCT04672525 |